Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Level BiotechnologyROCO:3118 +0.63%76 Days Inventory is 76.70 as of Dec. 2025, which is 16% above its 10-year median of 66.26. GuruFocus rates ROCO:3118 with a GF Score™ of 76/100 and a GF Value™ of NT$35.58 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 638 Biotechnology companies, Level Biotechnology ranks better than 79.94% on this metric.
The historical rank and industry rank for Level Biotechnology's Days Inventory or its related term are showing as below:
ROCO:3118'
s Days Inventory Range Over the Past 10 Years
Min: 49.13 Med: 66.26 Max: 81.44
Current: 74.61
During the past 13 years, Level Biotechnology's highest Days Inventory was 81.44. The lowest was 49.13. And the median was 66.26.
ROCO:3118's Days Inventory is ranked better than 79.94% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs ROCO:3118: 74.61
Level Biotechnology's Days Inventory
increased
from Dec. 2024 (64.98) to Dec. 2025 (76.70).
It might indicate that Level Biotechnology's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Level Biotechnology's Inventory Turnover for the
three
months ended in Dec. 2025 was 1.19.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Level Biotechnology's Inventory-to-Revenue for the
three
months ended in Dec. 2025 was 0.55.
Level Biotechnology (ROCO:3118) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Level Biotechnology's Inventory Turnover for the
three
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Level Biotechnology's Inventory to Revenue for the
three
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Level Biotechnology Days Inventory Related Terms
Level Biotechnology Days Inventory Historical Data
* Premium members only.
The historical data trend for Level Biotechnology's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3118 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Level Biotechnology's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Level Biotechnology Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Level Biotechnology's Days Inventory distribution charts can be found below:
* The bar in red indicates where Level Biotechnology's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Level Biotechnology (ROCO:3118) has a Days Inventory of 76.70 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Level Biotechnology and its competitors. This is 16% above median its historical median of 66.26. Over the past decade, Level Biotechnology's Days Inventory has ranged from 49.13 to 81.44. According to the industry distribution chart, Level Biotechnology ranks #128 out of 638 companies in the Biotechnology industry, placing it in the top 20.1%.
Is Level Biotechnology's Days Inventory too high?
Level Biotechnology's current Days Inventory of 76.70 is 16% above median its 10-year median of 66.26. Over the past 10 years, this metric has ranged from a low of 49.13 to a high of 81.44. The Biotechnology industry median Days Inventory is 183.20. Level Biotechnology's value of 76.70 is 58.1% below this industry median. Based on the distribution chart, Level Biotechnology ranks #128 out of 638 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Level Biotechnology has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Level Biotechnology's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Level Biotechnology ranks #128 out of 638 companies for Days Inventory. This places Level Biotechnology in the top 20% of its industry — outperforming the majority of peers. The industry median Days Inventory is 183.20. Level Biotechnology's value of 76.70 is 58.1% below this benchmark. Historically, Level Biotechnology's own Days Inventory has ranged from 49.13 to 81.44 over the past decade. While the company's 10-year median is 66.26 vs. the industry median of 183.20, Level Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Level Biotechnology's current Days Inventory of 76.70 is 58.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Level Biotechnology and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Level Biotechnology's current Days Inventory is 76.70, which is 16% above median its own 10-year median of 66.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Level Biotechnology (ROCO:3118) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$35.58, compared to a current price of NT$31.95 — trading 10.2% below its estimated fair value. The current Days Inventory is 76.70, which is 16% above median its 10-year median of 66.26 and 58.1% below the Biotechnology industry median of 183.20. Level Biotechnology's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Level Biotechnology (ROCO:3118), the current Days Inventory is 76.70 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Level Biotechnology (ROCO:3118) Overvalued in 2026?
Based on GuruFocus' analysis, Level Biotechnology stock appears to be undervalued.
The current stock price of NT$31.95 is trading 10.2% below its estimated GF Value™ of NT$35.58.
GuruFocus considers Level Biotechnology to be Modestly Undervalued.
Key valuation signals for ROCO:3118:
Days Inventory: 76.70 (16% above median its 10-year median of 66.26)
GF Value™: NT$35.58 vs. price of NT$31.95 (10.2% below fair value)
Industry Position: 58.1% below the Biotechnology median (#128 of 638)
No single metric tells the full story. See the ROCO:3118 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Level Biotechnology Inc is a Taiwan-based company engaged in the sales of biomedical products and providing preclinical testing services. The company has three reportable segments: Department A and B, Department C, and Department D. Department A and Department B sell the cell culture consumables and the antibody reagents, Department C sells the instruments and equipment, and Department D provides CRO services. The majority of revenue is derived from the Department A and B.
76GF Score
Get the complete analysis for ROCO:3118
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3118 has been successfully added to your 
